慢性髓性白血病诊断时附加染色体异常可独立预测疾病进展风险
在SPIRIT2试验中,763例初诊慢性期CML患者可评估诊断核型,其中27例存在特定附加染色体异常(ACAs)。ACAs对疾病进展的预测独立于Sokal和ELTS评分。
要点
- 初诊时存在特定ACAs(如8/19三体、iso17q、第二Ph、21三体、3q26.2、7/7q-、11q23、复杂核型)提示进展风险显著升高。
- ACAs患者进展率22.2% vs 无ACAs者2.2%,PFS的HR为5.21,FFP的HR为12.66。
- ACAs与Sokal/ELTS评分无关联,且在多变量分析中为PFS和FFP的独立预测因素。
核心结论
- 特定附加染色体异常是慢性期CML患者疾病进展的独立预测因素,其预测价值不依赖于Sokal或ELTS评分。
研究设计与样本
- 英国SPIRIT2试验比较伊马替尼400mg/日与达沙替尼100mg/日,814例入组患者中763例有诊断核型数据。
主要发现
- 27例存在原4大主要路径异常(8或19三体、iso17q或第二Ph)或5种新增病变(21三体、3q26.2、7/7q-、11q23、复杂核型)中任一/多项。
- Sokal或ELTS评分与ACAs存在无关联;单变量分析中高Sokal/ELTS评分和ACAs均与较差PFS相关,仅ACAs和高危ELTS评分与较差FFP相关。
- 多变量模型显示Sokal/ELTS评分和ACAs均为PFS的显著独立因素,仅ELTS评分和ACAs为FFP的显著独立因素。
关键数值与推荐
- ACAs定义为:8或19三体、iso17q、第二Ph、21三体、3q26.2、7/7q-、11q23或复杂核型中任一/多项。
临床怎么用
- 初诊CML患者应进行完整核型分析以识别上述ACAs,辅助风险分层。
- 存在ACAs提示进展风险高,无论Sokal/ELTS评分如何,应加强监测和随访。
局限性
- 基于SPIRIT2试验的事后分析,样本量有限(仅27例ACAs患者),结论需外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
At diagnosis of chronic-phase chronic myeloid leukemia (CML), there are conflicting data as to whether additional cytogenetic abnormalities (ACAs) beyond a standard Philadelphia (Ph) translocation confer a higher risk of subsequent disease progression. In the United Kingdom SPIRIT2 trial comparing imatinib 400 mg daily with dasatinib 100 mg daily, diagnostic karyotypes were available in 763 of the 814 patients recruited. Of these, 27 had ACAs in either/both the original 4 major route group (trisomy 8 or 19, iso17q or a second Ph) or the 5 additional lesions recently described (trisomy 21, 3q26.2, monosomy 7/7q-, 11q23, and complex karyotypes), and their progression rate was significantly higher (22.2%) than in patients without one of these ACAs (2.2%; P < .001). Patients with ACAs had worse progression-free survival (PFS; hazard ratio [HR], 5.21; 95% confidence interval [CI], 2.59-10.50; P < .001) and freedom from progression (FFP; HR, 12.66; 95% CI, 4.95-32.37; P < .001) compared with patients without ACAs. No association was seen between the Sokal or European Treatment and Outcome Study long-term survival (ELTS) scores and the presence of ACAs. Univariate analysis showed that higher Sokal and ELTS scores and the presence of ACAs were associated with poorer PFS, though only ACAs and high-risk ELTS scores were associated with poorer FFP. Multivariable models identified both the Sokal/ELTS score and ACAs as significant independent factors for PFS but only ELTS score and ACAs as significant independent factors for FFP. The data support the view that certain ACAs are predictive of disease progression independently of Sokal or ELTS scores.
引用
- Clark RE, Apperley JF, Copland M, et al. Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression. Blood Adv. 2021. PMID: 33616651. doi:10.1182/bloodadvances.2020003570
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。